Page 105 - 2021_04-Haematologica-web

Tumor suppressor activity of RXR in AML
56. Hernandez D, Palau L, Norsworthy K, et al. Overcoming microenvironment-mediated protection from ATRA using CYP26-resis- tant retinoids. Leukemia. 2020;34(11):3077- 3081.
57. Keeshan K, Vieugue P, Chaudhury S, et al. Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPalpha as a common target of TRIB1 and PML/RARA. Haematologica. 2016;101(10):1228-1236.
58. Lu Y, Yan JS, Xia L, et al. 2-bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia. Haematologica. 2019;104(1):102-112.
59. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic syner- gize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999;189(7):1043-1052.
60. Omidvar N, Maunakea ML, Jones L, et al.
PML-RARalpha co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica. 2013;98(3):424-427.
61. Coltella N, Valsecchi R, Ponente M, Ponzoni M, Bernardi R. Synergistic leukemia eradication by combined treat- ment with retinoic acid and HIF inhibition by EZN-2208 (PEG-SN38) in preclinical models of PML-RARalpha and PLZF- RARalpha-driven leukemia. Clin Cancer Res. 2015;21(16):3685-3694.
haematologica | 2021; 106(4)
1021